

Cross reactivity of the binary toxins Anthrax- and C2-toxin

Monica Rolando^{1,2}, **Angelika Kronhardt**³, Christoph Beitzinger³, Michael Leuber³,
Gilles Flatau¹, Michel R. Popoff⁴, Emmanuel Lemichez^{1,2,5} and Roland Benz^{3,6}

¹Inserm, U895, Toxines microbiennes dans la relation hôte-pathogènes, Batiment Archimed, Nice, France; ²Université de Nice-Sophia Antipolis, UFR Médecine, IFR50, Nice, France; ³Rudolf-Virchow-Center, DFG-Research Center for Experimental Biomedicine, University of Würzburg, Germany; ⁴Unité des Bactéries Anaerobies et Toxines, Institut Pasteur, Paris, France; ⁵Laboratoire central de bactériologie, CHU Nice, France; ⁶School of Engineering and Science, Jacobs University Bremen, Germany

Binary toxins are among the most potent bacterial protein toxins. They perform a cooperative mode of translocation and exhibit fatal enzymatic activities in eukaryotic cells. Anthrax- and C2-toxin are the most prominent examples for this A-B type of toxins. To investigate the mechanism of translocation into target cells and the possible cross reactivity of toxin translocation we performed various *in vitro* and *in vivo* experiments by interchanging the different A-B components of Anthrax- and C2-toxins. The enzymatic components of one toxin were combined with the homologous binding component of the other toxin. Although the binding and translocation components protective antigen (PA₆₃) and C2II share a sequence homology of about 35%, the results indicate biochemical and functional differences between both binding proteins. *In vitro* measurements using the black lipid bilayer showed that Anthrax edema factor (EF) and lethal factor (LF) bind to channels formed by the binding component C2II of C2-toxin and that C2-toxin's enzymatic component C2I binds to PA₆₃-pores. Furthermore, we could demonstrate that *in vivo* the PA₆₃-channel has the ability to transport the enzymatic moiety C2I into target cells, causing actin modification and cell rounding, whereas C2II-channel are not able to transport EF or LF. Our findings support the commonly accepted mode of translocation of A-B toxins and, in addition, we present first-time evidence that a heterogenic combination of enzymatic and translocation components also exhibit toxicity to primary human endothelial cells (HUVECs).